Post Market Study of the 3DKnee™ With E-plus Insert

Osteoarthritis Clinical Trial

— e-plus  

Official title:

Prospective Multicenter Open Label Study Examining the Mid- and Long-term Safety and Efficacy of the 3DKnee™ System With Vitamin E UHMWPE Tibial Inserts (3DKnee™ With E-plus Insert)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01551472
• Other study ID #: PS-706
• Status: Terminated
• Start date: April 2012
• Est. completion date: January 2022

Study information

• Verified date: February 2022
• Source: Encore Medical, L.P.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the use and efficacy of the 3DKnee™ System using Vitamin E UHMWPE tibial inserts for total knee replacement surgery.

Description:

Total knee replacement surgery is widely accepted as effective treatment for degenerative joint disease (DJD), osteoarthritis and rheumatoid arthritis. Relief of patient pain and return of mobility are the primary goals that can be accomplished by this surgery. Currently available prosthetic designs accomplish these goals and the surgery has been defined as one of the most successful operations available to improve the quality of life for patients with DJD. This study will evaluate subjects who are candidates for a total knee replacement and meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 175
• Est. completion date: January 2022
• Est. primary completion date: January 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subject must be a candidate for a total primary knee replacement.

• Subject must have knee joint disease related to degenerative joint disease, including osteoarthritis or traumatic arthritis

• Subject has a BMI = 40.00 kg/m2

• Subject is likely to be available for evaluation for the duration of the study

• Subject is able and willing to sign the informed consent and follow study procedures

• Subject is not pregnant

• Subject must be between age 40 and age 75 at the time of consent

Exclusion Criteria:

• Subject has had a prior total or uni-knee replacement on this knee in the past (no revisions allowed in study)

• Subject has avascular necrosis of the femoral condyles, post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy, moderate valgus, varus, or flexion deformities or rheumatoid arthritis

• Subject has an active cancer or is a survivor for <5 years except for squamous cell or basal cell skin cancer

• Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol

• Subject is currently a documented substance abuser (alcohol or other addictions)

• Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic

• Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity

• Subject has a BMI > 40.00 kg/m2

• Subject has loss of ligamentous structures

• Subject has high levels of physical activity and is unwilling to modify levels of physical activity commensurate with recommendations

• Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)

• Subject is a prisoner

• Subject is pregnant

• Subject has known materials sensitivity (to metals)

• Subject is younger than 40 years (<40) or older than 75 years (>75) at the time of consent

Related Conditions & MeSH terms

• Degenerative Joint Disease
• Joint Diseases
• Osteoarthritis
• Traumatic Arthritis

Intervention

Device:
• 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.

Locations

Country	Name	City	State
United States	New Mexico Orthopedics	Albuquerque	New Mexico
United States	Texas Institute for Hip and Knee Surgery	Austin	Texas
United States	Orthopaedic Surgery Specialists	Burbank	California
United States	Institute for Orthopaedic Surgery and Sports Medicine	Fort Myers	Florida
United States	Orthopedic Specialists of North County	Oceanside	California
United States	St. Peter's Bone & Joint Surgery	Saint Peters	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Encore Medical, L.P.	DJO Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the Vitamin E UHMWPE as part of the total knee system, measured by Knee Society Score Evaluation and total number of radiologic failures of the device.	The (American) Knee Society Score has both an objective and a functional component. The objective score takes into account pain, flexion, stability, alignment, extension lag and flexion contracture. Overall success will be defined as a KSS score = 80 at two years.; Radiolucencies have been defined as two types, with one type being more common than the other. In the case of physiologic radiolucency, which is the most common type of radiolucency seen, there is a narrow line present that is well-defined around the prosthesis. This line is surrounded by a radio-dense line and tends to consolidate (disappear) within the first year. The second type of radiolucency, the pathologic radiolucency, is rarer and is associated with loosening and infection. It is a progressive, poorly defined radiolucency that is more than 2 mm thick and without a radiolucent line.	2 year
Secondary	Change in Knee Society Score from pre-surgery to 10 years	The Knee Society Score includes a knee rating and function score. This evaluation covers the knee rating score with three main parameters of pain, stability and range of motion and that flexion contracture, extension lag and misalignment should be dealt with as deductions. Thus, 100 points will be obtained by a well-aligned knee with no pain, 125 degrees of motion, and negligible anteroposterior and mediolateral instability. 50 points are allotted for pain, 25 for stability, and 25 for range of motion. Grading for KS Score: Excellent (90-100), Good (80-90), Fair (70-79) and Poor (<70).	10 year
Secondary	Change in WOMAC Osteoarthritis Index from pre-surgery to 10 years	The Western Ontario McMaster Arthritis Index is a set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip. It can be self-administered. It assesses the pain, joint stiffness, physical, social & emotional function of a person with osteoarthritis in determining the overall level of disability.	10 year
Secondary	Change in Oxford Knee Score from pre-surgery to 10 years	The Oxford Knee Score (OKS) is a patient-based outcomes measure consisting of 12 questions that is sensitive, simple and validated. It is based on a maximum score of 48.	10 year
Secondary	Change in response to Quality of Life questions from pre-surgery to 6 months and each year thereafter through 10 years		10 years
Secondary	6. Change in pain from pre-surgery to 6 months and each year thereafter through 10 years		10 years